SCHEMBL3240308

SCHEMBL3240308

Cc1cccc(COc2c(-c3csc(C(=O)N4CCC(Cc5ccccc5)CC4)n3)cc(Br)c(O)c2Br)n1

nearest known ligand 0.43

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
CYP46A1 Q9Y6A2 1/20 0.41
SMN1; SMN2 Q16637 2/20 0.38
MGLL Q99685 5/20 0.38
ALDH1A1 P00352 1/20 0.38
HTT P42858 1/20 0.38
CYP2C9 P11712 1/20 0.38
CYP2C19 P33261 1/20 0.38
HTR2B P41595 1/20 0.38
MAPK14 Q16539 1/20 0.38
MEN1 O00255 1/20 0.38
KMT2A Q03164 1/20 0.38
ABHD6 Q9BV23 1/20 0.37
GRIN2D O15399 1/20 0.37
GRIN3B O60391 1/20 0.37
GRIN1 Q05586 1/20 0.37
GRIN2A Q12879 1/20 0.37
GRIN2B Q13224 1/20 0.37
GRIN2C Q14957 1/20 0.37
GRIN3A Q8TCU5 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3236551 0.84 CYP46A1 (0.40) CYP46A1MEN1KMT2AGRIN2DGRIN3B
SCHEMBL3232554 0.84 MEN1 (0.41) CYP46A1SMN1; SMN2MGLLALDH1A1HTT
SCHEMBL3232447 0.84 L3MBTL1 (0.40) CYP46A1SMN1; SMN2MGLLALDH1A1HTT
SCHEMBL3237518 0.83 CYP46A1 (0.46) CYP46A1SMN1; SMN2GRIN2DGRIN3BGRIN1
SCHEMBL3247535 0.81 GAA (0.43) CYP46A1SMN1; SMN2ALDH1A1MEN1KMT2A
SCHEMBL3823682 0.80 ALDH1A1 (0.39) CYP46A1SMN1; SMN2MGLLALDH1A1CYP2C9
SCHEMBL8393758 0.79 SMN1; SMN2 (0.38) SMN1; SMN2MGLLCYP2C9CYP2C19HTR2B
SCHEMBL3244022 0.79 CYP46A1 (0.41) CYP46A1SMN1; SMN2MGLLCYP2C9CYP2C19
SCHEMBL8018991 0.77 L3MBTL1 (0.41) CYP46A1SMN1; SMN2MGLLALDH1A1HTT
SCHEMBL3240073 0.77 CYP46A1 (0.48) CYP46A1SMN1; SMN2MGLLCYP2C9CYP2C19

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100099677-A1 Compounds, Compositions and Methods Comprising Thiazole Derivatives INSTITUTE FOR ONEWORLD HEALTH 2010-04-22 US claimed
WO-2009131952-A1 COMPOUNDS, COMPOSITIONS AND METHODS COMPRISING THIAZOLE DERIVATIVES INSTITUTE FOR ONEWORLD HEALTH (US) 2009-10-29 WO claimed
US-20100144733-A1 Compounds, compositions and methods comprising heteroaromatic derivatives INSTITUTE FOR ONEWORLD HEALTH 2010-06-10 US disclosed
US-20100144733-A1 Compounds, compositions and methods comprising heteroaromatic derivatives INSTITUTE FOR ONEWORLD HEALTH 2010-06-10 US disclosed
US-20100144733-A1 Compounds, compositions and methods comprising heteroaromatic derivatives INSTITUTE FOR ONEWORLD HEALTH 2010-06-10 US disclosed
US-20100099677-A1 Compounds, Compositions and Methods Comprising Thiazole Derivatives INSTITUTE FOR ONEWORLD HEALTH 2010-04-22 US disclosed
US-20100099677-A1 Compounds, Compositions and Methods Comprising Thiazole Derivatives INSTITUTE FOR ONEWORLD HEALTH 2010-04-22 US disclosed
US-20100099677-A1 Compounds, Compositions and Methods Comprising Thiazole Derivatives INSTITUTE FOR ONEWORLD HEALTH 2010-04-22 US disclosed
US-20090318429-A1 Compounds, Compositions and Methods Comprising Heteroaromatic Derivatives INSTITUTE FOR ONEWORLD HEALTH 2009-12-24 US disclosed
US-20090318429-A1 Compounds, Compositions and Methods Comprising Heteroaromatic Derivatives INSTITUTE FOR ONEWORLD HEALTH 2009-12-24 US disclosed
US-20090318429-A1 Compounds, Compositions and Methods Comprising Heteroaromatic Derivatives INSTITUTE FOR ONEWORLD HEALTH 2009-12-24 US disclosed
WO-2009131952-A1 COMPOUNDS, COMPOSITIONS AND METHODS COMPRISING THIAZOLE DERIVATIVES INSTITUTE FOR ONEWORLD HEALTH (US) 2009-10-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100144733-A1 Compounds, compositions and methods comprising heteroaromatic derivatives CFTR, PKD1, PKD2 CYP46A1 215/4885SMN1; SMN2 4546/4885MGLL 3833/4885
US-20100099677-A1 Compounds, Compositions and Methods Comprising Thiazole Derivatives CFTR, PKD1, PKD2 CYP46A1 983/4885SMN1; SMN2 4068/4885MGLL 2619/4885
US-20090318429-A1 Compounds, Compositions and Methods Comprising Heteroaromatic Derivatives CFTR, PKD1, PKD2 CYP46A1 215/4885SMN1; SMN2 4546/4885MGLL 3833/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.